BioSpace News Archive

Frustrated by your job search? Does your dream employer rarely have openings? A little-known technique – the job proposal approach – can open doors for you.

Treatment with Erleada plus androgen deprivation therapy resulted in a 25% reduction in the risk of death compared to placebo in prostate cancer patients.

Scientists from the University of Michigan have created a device that can mass-produce human embryo-like structures, according to a recent NPR report. The synthetic, living objects closely resemble a primitive form of human embryos.

Current Chief Executive Officer Albert Bourla will succeed Read as chairman on Jan. 1, 2020 and will continue to serve as CEO.

The Massachusetts Biotechnology Council recently released a 2019 transportation survey for the Bay State that shows 60% of respondents would change jobs for a better commute.

AbbVie’s Mayvret won expanded approval from the U.S. Food and Drug Administration to shorten the one-daily treatment duration from 12 to eight weeks in treatment-naïve hepatitis C patients without cirrhosis and with compensated cirrhosis.

The FDA’s latest approval for Darzalex is based on results from the Phase III CASSIOPEIA trial that showed the addition of Darzalex to VTd before and after ASCT resulted in deeper responses in patients with the blood cancer.

Pfizer announced positive top-line results from the first trial in May.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced that Vu Truong, Ph.D., Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 11:15 am ET.

Aridis Pharmaceuticals, Inc. announced it will present two posters at the Infectious Disease Society of America’s IDWeek™ 2019, taking place October 2-6 in Washington, DC.